pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 fusion protein TA-CIN vaccine PVX-2

{
  "id": "MLC-T-ONC-016132",
  "term": "pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 fusion protein TA-CIN vaccine PVX-2",
  "field": "Oncology and biomedicine",
  "definition": "A cancer vaccine consisting of a combination of two vaccines, a prime pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and a boost HPV16 L2/E6/E7 fusion protein TA-CIN vaccine, with potential immunostimulating and antineoplastic activities. pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine is an antigen-specific DNA cancer vaccine consisting of the coding sequences of a signal peptide (pNGVL4a-Sig), a detox form of the human papillomavirus type 16 (HPV-16) antigen E7, and the heat shock protein 70 (HSP70). Upon administration, this prime vaccine may generate potent cytotoxic CD8(+) T-cell responses against E7-expressing tumor cells, resulting in tumor cell death. HPV16 L2/E6/E7 fusion protein TA-CIN vaccine is a recombinant human papillomavirus (HPV), genetically engineered fusion protein vaccine in which the three HPV16 viral proteins L2, E6 and E7 are fused together in a single tandem fusion protein (TA-CIN; HPV16 L2\\E6\\E7). Upon administration, this boost vaccine may stimulate the immune system to generate HPV16 E6\\E7-specific CD4+ and CD8+ T-cell responses as well as the induction of L2-specific antibodies. In addition, this vaccine may prevent infection and the development of other HPV16-associated diseases. L2, a minor viral capsid protein, is able to induce a strong antibody response against certain HPV types.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/pngvl4a-sig-e7-detox-hsp70-dna-and-hpv16-l2-e6-e7-fusion-protein-ta-cin-vaccine/"
}